A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)
Status:
Recruiting
Trial end date:
2025-05-19
Target enrollment:
Participant gender:
Summary
The reason for this long term study is to see how safe and effective the study drug known as
baricitinib is in participants with systemic lupus erythematosus (SLE) who have completed the
final treatment visit of study I4V-MC-JAHZ (NCT03616912) or study I4V-MC-JAIA (NCT03616964).